The National Institutes of Health (NIH) is concerned about a potential coronavirus vaccine being developed by British manufacturer AstraZeneca after a test subject had an adverse reaction during clinical trials, The L.A. Times reported. Authorities in Britain, however, have allowed the pharmaceutical company to resume its research into the potentially life-saving drug.
As previously reported by The Inquisitr, the Cambridge, England-based pharmaceutical company has been conducting large-scale clinical trials, involving thousands of volunteers, on a potential coronavirus vaccine it developed in conjunction with a British university. AZD1222. also known as the “Oxford vaccine,” showed great promise during animal testing, and has moved into clinical trials on human test subjects.
Unfortunately, those tests had to be halted once a patient got sick. A British review board, the Medicines Health Regulatory Authority (MHRA), investigated the circumstances behind the patient getting sick and, after its investigation, cleared the manufacturer to resume its trials — at least, in the U.K.
0 comments :
Post a Comment